Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
The carrier of bone morphogenetic protein (BMP) type II receptor (BMPR-II) mutation implicates poor prognosis in pulmonary hypertension. However, we previously reported that the prognosis after combination therapy would be better in mutation carrier than in noncarrier. In this study, an analysis of 26 cases of idiopathic pulmonary hypertension (IPAH) (7 cases with BMPR2 gene mutation positive and 19 cases with negative) showed that baseline right ventricular function was better in carrier than in noncarrier, but the right ventricular function after combination therapy was significantly better in the carrier than in the noncarrier.
|